Drug news
FDA to review vismodegib(Genentech) for Basal Cell Carcinoma
The FDA will review vismodegib from Genentech/Roche, being the first-in-class oral treatment that inhibits signalling in the Hedgehog pathway which is implicated in more than 90% of Basal Cell Carcinoma cases.The FDA review is planned to take place on 8 March 2012. The filing is supported by the ERIVANCE BCC study.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.